Medicine information AVONEX 30mcg BIO-SET 30mcg(6 mil.UI) powder and solvent for solution for injection

Product code:
W42705001
Quantity:
4
Indicated for:
multiple sclerosis
Route of administration:
injectable
Substance:
interferon beta 1A (interferon)
ATC
L03AB07 — Antineoplastic and immunomodulating agents | Immunostimulants | Immunostimulants | Interferons
Interferon beta-1A is a medication used for the treatment of relapsing multiple sclerosis. It works by modulating the immune response, reducing the frequency of relapses and slowing disease progression.

The medication is administered as a subcutaneous or intramuscular injection, as directed by a doctor, usually once or several times a week. It is important for patients to follow the treatment regimen and undergo regular check-ups.

Patients should be aware of potential side effects, such as flu-like symptoms, injection site reactions, or fatigue. It is important to inform the doctor of any unusual symptoms.

Common side effects include flu-like symptoms, injection site reactions, and fatigue. In rare cases, severe reactions such as depression or liver impairment may occur. Patients should be informed of these risks before starting treatment.

General data about AVONEX 30mcg BIO-SET 30mcg(6 mil.UI)

Substance:
interferon beta 1A
Date of latest medicines list:
01-07-2020
Product code:
W42705001
Strength:
30mcg(6 mil.UI)
Pharmaceutical form:
powder and solvent for solution for injection
Quantity:
4
Product type:
Original
Prescription status:
P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.

Marketing authorisation

Manufacturer:
BIOGEN (DENMARK) MANUFACTURING APS - DANEMARCA
Holder:
BIOGEN NETHERLANDS B.V. - OLANDA
Number:
33/2001/02
Shelf life:
2 years

Strengths available for interferon beta 1A

  • 22mcg/0.5ml
  • 30mcg
  • 30mcg(6 mil.UI)
  • 30mcg/0.5ml
  • 44mcg
  • 44mcg/0.5ml
  • 8.8mcg/22mcg

Official documents

The SmPC text is not displayed because a match to this medicine, strength and pharmaceutical form has not been confirmed.

The correspondence between the document and the displayed text is unconfirmed.

Source institution
EMA
Document language
English
Source record: first published
19/03/2009
Source record: last updated
26/05/2026